It is known that the HER2 protein is overexpressed in 20% of lung cancer cases, but treatment with trastuzumab in this group has not been beneficial except probably in 1–2% of cases with a HER2 gene driver mutation (49). This evidence concerns the gene ERBB2 and lung carcinoma.